Description
Brazil
Canada - English
Canada - Français
Deutschland
France
Ελλάδα
Ireland
Latin America
Spain
United Kingdom
United States
日本
Only a truly predictive test can identify the right treatment for the right patient
TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy
Only the Oncotype DX Breast Recurrence Score test is incorporated in the four major international guidelines and recommended by two major EU health technology assessment (HTA) bodies.
This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.